The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

SLEEP (Annual Meeting of the Associated Professional Sleep Societies)
June 7th – 11th 2025, Seattle, WA
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Sleep-wake disorders
POSTER
The Clinical and Humanistic Burden of Narcolepsy: Matched Analysis of US National Health and Wellness Survey Data
AUTHOR(S)

Kiran P. Maski,1 Michael J. Doane,2 M. Janelle Cambron-Mellott,3 Shakiba Eslamimehr,3 Adam Jauregui,3 Wilbur P. Williams, III2

Sleep-wake disorders
POSTER
Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Kiran Maski,4 Jandira Ramos,5 Yangchun Du,5 Alexandra Lovett,5 Marcus Yountz,5 Bhaskar Rege5

Sleep-wake disorders
POSTER
Evaluation of Cardiac Safety Profile of ALKS 2680 in Healthy Subjects: Concentration-QTc Relationship of ALKS 2680
AUTHOR(S)

Jahnavi Kharidia,1 Borje Darpo,2 Sergey Yagoda,1 Alexandra Lovett,1 Hongqi Xue,2 Hailu Chen,1 Bhaskar Rege,1 Ishani Landry1

Sleep-wake disorders
POSTER
Diagnosis Journey, Symptoms, and Burden of Idiopathic Hypersomnia: Patient Perspectives from Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 and Wilbur P. Williams, III1

Sleep-wake disorders
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy or Idiopathic Hypersomnia: A Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Derek Matthies,2 Shifang Liu,2 Sergey Yagoda,2 Bhaskar Rege2

Sleep-wake disorders
POSTER
Evaluation of the Novel Orexin 2 Receptor Agonist ALKS 2680 on Measures of Arousal Circuit Activation in Rodents
AUTHOR(S)

Julie M. Brooks,1 Angelica M. Patino,1 Corey B. Puryear,1 Laura A. Tan,1 Brian Raymer1

Sleep-wake disorders
PRESENTATION
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients with Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Presented by Julia Chapman

Sleep-wake disorders
PRESENTATION
Investigational Orexin-2 Receptor Agonists for Narcolepsy Types 1 and 2, Idiopathic Hypersomnia, and Beyond
AUTHOR(S)

Presented by Marcus Yountz

Sleep-wake disorders
ENCORE POSTER
The Economic Burden of Narcolepsy: Matched Analysis of US National Health and Wellness Survey Data
AUTHOR(S)

Michael Doane,1 Kiran P. Maski,2 M. Janelle Cambron-Mellott,3 Shakiba Eslamimehr,3 Adam Jauregui,3 Wilbur P. Williams, III1